Our work suggests that VRK1 synergize with MYCN to drive NB progression and that VRK1 inhibition may constitute a novel cell-cycle-targeted strategy for anticancer therapy in neuroblastoma. This evidence concerns the gene VRK1 and neuroblastoma.